Skip to main content

Antibody-Directed Enzyme Prodrug Therapy

  • Reference work entry
  • First Online:
Encyclopedia of Cancer
  • 97 Accesses

Synonyms

ADEPT

Definition

Antibody-directed enzyme-prodrug therapy (ADEPT) is a two-step concept for the immunologically targeted application of chemotherapeutic agents to tumor tissue. In it, first a tumor-specific antibody coupled to a prodrug-specific enzyme is applied systemically via a parenteral route. Once this antibody-enzyme-construct has bound to its cognate antigen in tumor tissue and the unbound remainder has cleared from the bloodstream, the prodrug is administered systemically. Ideally, it is converted into active cytotoxic drug exclusively in tumor tissue by the tumor-bound enzyme component of the targeting construct.

Characteristics

In theory, this concept provides obvious advantages: The cytotoxic drug will only be liberated in tumor tissue and thus the therapeutic index will theoretically be increased by the factor of toxicity of cytotoxic drug compared to prodrug. This means less side effects with the same efficacy or increased efficacy with the same toxicity – the...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 2,499.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 3,999.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Bagshawe KD (1989) The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites. Br J Cancer 60:275–281

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bagshawe KD, Sharma SK, Begent RH (2004) Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin Biol Ther 4:1777–1789

    Article  CAS  PubMed  Google Scholar 

  • Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O’Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RH (2002) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer 87:600–607

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schellmann N, Deckert PM, Bachran D, Fuchs H, Bachran C (2012) Targeted enzyme prodrug therapies. Mini Rev Med Chem 10(10):887–904

    Article  Google Scholar 

  • Sharma SK, Bagshawe KD, Springer CJ, Burke PJ, Rogers GT, Boden JA, Antoniw P, Melton RG, Sherwood RF (1991) Antibody directed enzyme prodrug therapy (ADEPT): a three phase system. Dis Markers 9:225–231

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P. Markus Deckert .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this entry

Cite this entry

Deckert, P.M. (2014). Antibody-Directed Enzyme Prodrug Therapy. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46875-3_7059

Download citation

Publish with us

Policies and ethics